H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

July 23, 2026 7:10 AM

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $100.00 price target on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found